JY
ATOS icon

Jeff Yass’s Atossa Therapeutics ATOS Stock Holding History

Jeff Yass’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.1K Buy
+15,574
New +$71K ﹤0.01% 12959
2026
Q1 		– Sell
-38,839
Closed -$246K – 13132
2025
Q4 		$344K Buy
38,839
+24,199
+165% +$306K ﹤0.01% 9623
2025
Q3 		$190K Sell
14,640
-3,621
-20% -$44.7K ﹤0.01% 11045
2025
Q2 		$227K Sell
18,261
-11,095
-38% -$133K ﹤0.01% 10943
2025
Q1 		$296K Buy
29,356
+14,278
+95% +$173K ﹤0.01% 10095
2024
Q4 		$214K Buy
15,078
+10,293
+215% +$201K ﹤0.01% 10595
2024
Q3 		$109K Buy
+4,785
New +$96.6K ﹤0.01% 11000
2024
Q2 		– Sell
-18,141
Closed -$401K – 12004
2024
Q1 		$490K Buy
18,141
+4,478
+33% +$71.9K ﹤0.01% 8565
2023
Q4 		$180K Sell
13,663
-2,904
-18% -$31.3K ﹤0.01% 10788
2023
Q3 		$183K Sell
16,567
-8,302
-33% -$120K ﹤0.01% 10323
2023
Q2 		$470K Buy
24,869
+17,826
+253% +$216K ﹤0.01% 8467
2023
Q1 		$76.6K Buy
7,043
+610
+9% +$6.8K ﹤0.01% 11466
2022
Q4 		$51K Buy
+6,433
New +$73.9K ﹤0.01% 11391
2022
Q3 		– Sell
-5,203
Closed -$75.6K – 13125
2022
Q2 		$85K Sell
5,203
-1,800
-26% -$28.4K ﹤0.01% 11617
2022
Q1 		$131K Buy
7,003
+2,193
+46% +$44.6K ﹤0.01% 11690
2021
Q4 		$115K Sell
4,810
-11,658
-71% -$427K ﹤0.01% 12035
2021
Q3 		$805K Sell
16,468
-156,344
-90% -$9.09M ﹤0.01% 8112
2021
Q2 		$16.4M Buy
172,812
+169,528
+5,162% +$8.98M ﹤0.01% 2278
2021
Q1 		$104K Sell
3,284
-3,879
-54% -$142K ﹤0.01% 11842
2020
Q4 		$102K Buy
7,163
+3,759
+110% +$87K ﹤0.01% 10482
2020
Q3 		$124K Sell
3,404
-1,353
-28% -$65K ﹤0.01% 9800
2020
Q2 		$271K Buy
+4,757
New +$169K ﹤0.01% 8524
2018
Q3 		– Sell
-1,611
Closed -$53K – 9175
2018
Q2 		$53K Sell
1,611
-68
-4% -$3.65K ﹤0.01% 9256
2018
Q1 		$135K Buy
+1,679
New +$156K ﹤0.01% 8578

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's ATOS Position: Q2 2026 in Review

Jeff Yass opened a new position in Atossa Therapeutics (ATOS) in Q2 2026: 15,574 shares worth $30.1K. The stake represents ﹤0.01% of the portfolio and ranks #12959 among its holdings. This is a return to the name: Jeff Yass previously reported a position in ATOS as recently as Q4 2025.

Jeff Yass first reported a position in ATOS in Q1 2018 and has held it in 24 quarters since. The position peaked at $16.4M in Q2 2021. 31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

  • Jeff Yass held 15,574 shares of Atossa Therapeutics worth $30.1K as of Q2 2026.
  • Atossa Therapeutics was a new Jeff Yass position in Q2 2026.
  • Atossa Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12959 holding.
  • Jeff Yass first reported a position in Atossa Therapeutics in Q1 2018 and has held it in 24 quarters since.
  • Jeff Yass's Atossa Therapeutics position peaked at $16.4M in Q2 2021.
  • 31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.